Marieke J. Pierik

Dr. Marieke J. Pierik


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in The Lancet
Verified
Journal Article
Closed access
MJMarin J de Jong
Marin J de Jong
AJAndrea E van der Meulen-De Jong
Andrea E van der Meulen-De Jong
MRMariëlle J Romberg-Camps
Mariëlle J Romberg-Camps
MBMarco C Becx
Marco C Becx
JMJeroen Maljaars
Jeroen Maljaars
MPMarieke J. Pierik
Marieke J. Pierik

1 April 2018 in Gastroenterology
Verified
Journal Article
Closed access
GDGeert R. D’Haens
Geert R. D’Haens
SVSeverine Vermeire
Severine Vermeire
GLGuy Lambrecht
Guy Lambrecht
FBFilip Baert
Filip Baert
PBPeter Bossuyt
Peter Bossuyt
SWSabrina Williams
Sabrina Williams

22 May 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
VBVince B. C. Biemans
Vince B. C. Biemans
CWC. Janneke van der Woude
C. Janneke van der Woude
GDGerard Dijkstra
Gerard Dijkstra
AJAndrea E. van der Meulen‐De Jong
Andrea E. van der Meulen‐De Jong
MLMark Löwenberg
Mark Löwenberg
T(The Dutch Initiative On Crohn And Colitis (Icc)
The Dutch Initiative On Crohn And Colitis (Icc)
Summary: Background: Both vedolizumab and ustekinumab can be considered for the treatment of Crohn’s disease (CD) when anti‐TNF treatment fails. However, head‐to‐head trials are currently not available or planned.Aim: To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective registry specifically developed for comparative studies with correction for confounders.Methods: Crohn´s disease patients, who failed anti‐TNF treatment and started vedolizumab or ustekinumab in standard care as second‐line biological, were identified in the observational prospective Dutch Initiative on Crohn and Colitis Registry. Corticosteroid‐free clinical remission (Harvey Bradshaw Index ≤4), biochemical remission (C‐reactive protein ≤5 mg/L and fecal calprotectin ≤250 µg/g), combined corticosteroid‐free clinical and biochemical remission, and safety outcomes were compared after 52 weeks of treatment. To adjust for confounding and selection bias, we used multiple logistic regression and propensity score matching.Results: In total, 128 vedolizumab‐ and 85 ustekinumab‐treated patients fulfilled the inclusion criteria. After adjusting for confounders, ustekinumab‐treated patients were more likely to achieve corticosteroid‐free clinical remission (odds ratio [OR]: 2.58, 95% CI: 1.36‐4.90, P = 0.004), biochemical remission (OR: 2.34, 95% CI: 1.10‐4.96, P = 0.027), and combined corticosteroid‐free clinical and biochemical remission (OR: 2.74, 95% CI: 1.23‐6.09, P = 0.014), while safety outcomes (infections: OR: 1.26, 95% CI: 0.63‐2.54, P = 0.517; adverse events: OR: 1.33, 95% CI: 0.62‐2.81, P = 0.464; hospitalisations: OR: 0.67, 95% CI: 0.32‐1.39, P = 0.282) were comparable between the two groups. The propensity score matched cohort with sensitivity analyses showed comparable results.Conclusions: Ustekinumab was associated with superior effectiveness outcomes when compared to vedolizumab, while safety outcomes were comparable after 52 weeks of treatment in CD patients who have failed anti‐TNF treatment.

1 May 2018 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MJMarin J. de Jong
Marin J. de Jong
RHRoxanne Huibregtse
Roxanne Huibregtse
AMAd A.M. Masclee
Ad A.M. Masclee
DJDaisy M.A.E. Jonkers
Daisy M.A.E. Jonkers
MPMarieke J. Pierik
Marieke J. Pierik

1 July 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MJMarin J. de Jong
Marin J. de Jong
ABAnnelies Boonen
Annelies Boonen
AJAndrea E. van der Meulen-De Jong
Andrea E. van der Meulen-De Jong
MRMariëlle J. Romberg-Camps
Mariëlle J. Romberg-Camps
ABAd A. van Bodegraven
Ad A. van Bodegraven
MPMarieke J. Pierik
Marieke J. Pierik

1 April 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
VBVince B. C. Biemans
Vince B. C. Biemans
JSJasmijn A. M. Sleutjes
Jasmijn A. M. Sleutjes
AVAnnemarie C. de Vries
Annemarie C. de Vries
ABAlexander G. L. Bodelier
Alexander G. L. Bodelier
GDGerard Dijkstra
Gerard Dijkstra
T(The Dutch Initiative On Crohn And Colitis (Icc)
The Dutch Initiative On Crohn And Colitis (Icc)
Summary: Background: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC).Aim: To evaluate effectiveness, safety and use of tofacitinib in daily practice.Methods: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Corticosteroid‐free clinical remission (short clinical colitis activity index [SCCAI] ≤2), biochemical remission (faecal calprotectin level ≤250 µg/g), combined corticosteroid‐free clinical and biochemical remission, predictors of remission, safety outcomes, treatment dose and effect on lipids were determined at weeks 12 and 24. Endoscopic outcomes were evaluated in centres with routine endoscopic evaluation.Results: In total, 123 UC patients (95% anti‐TNF, 62% vedolizumab and 3% ustekinumab experienced) were followed for a median duration of 24 weeks (interquartile range 12‐26). The proportion of patients in corticosteroid‐free clinical, biochemical, and combined corticosteroid‐free clinical and biochemical remission rate at week 24 was 29% (n: 22/77), 25% (n: 14/57), and 19% (n: 11/57) respectively. Endoscopic remission (Mayo = 0) was achieved in 21% of patients at week 12 (n: 7/33). Prior vedolizumab exposure was associated with reduced clinical remission (odds ratio 0.33, 95% confidence interval [CI] 0.11‐0.94). At week 24, 33% (n: 14/42) of patients still on tofacitinib treatment used 10 mg twice daily. In total, 33 tofacitinib‐related adverse events (89 per 100 patient years) occurred, 7 (6% of total cohort) resulted in discontinuation. Cholesterol, HDL and LDL levels increased during induction treatment by 18% (95% CI 9‐26), 18% (95% CI 8‐28) and 21% (95% CI 14‐39) respectively.Conclusion: Tofacitinib is an effective treatment for UC after anti‐TNF and vedolizumab failure. However, a relatively high rate of adverse events was observed resulting in discontinuation in 6% of patients.